Disorders of blood clotting;Basiswissen gerinnungslabor

Deutsches Arzteblatt

Volumn 104, Issue 21, 2007, Pages

  Luxembourg, Beate ^a   Krause, Manuela ^b   Lindhoff Last, Edelgard ^a  

^a GOETHE UNIVERSITY   (Germany)

^b DEUTSCHE KLINIK FÜR DIAGNOSTIK   (Germany)

Author keywords

Bleeding diathesis; Coagulation; Diagnosis; Thromboembolism; Thrombophilia

Indexed keywords

BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 8; PHOSPHOLIPID ANTIBODY; PROTEIN C; PROTHROMBIN;

ACTIVATED PROTEIN C RESISTANCE; ANAMNESIS; ANTITHROMBIN DEFICIENCY; BLEEDING TENDENCY; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; CLINICAL FEATURE; CONGENITAL DISORDER; GENE MUTATION; LABORATORY TEST; PARTIAL THROMBOPLASTIN TIME; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; PROTHROMBIN TIME; REVIEW; RISK FACTOR; THROMBOCYTE FUNCTION;

EID: 34447292088     PISSN: 00121207     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. McFarlane RG: An enzyme cascade in the blood clotting mechanism and its function as a biological amplifier. Nature 1964; 202: 498-9.
2. Spannagl M, Moessmer G: Hämostaseologische Globalteste. Hämostaseologie 2006; 1: 27-37.
3. Barthels M, von Depka M: Das Gerinnungskompendium. Stuttgart: Thieme Verlag 2003.
4. Pötzsch B, Madlener K: Gerinnungskonsil, Rationelle Diagnostik und Therapie von Gerinnungsstörungen. Stuttgart: Thieme Verlag 2002.
5. Koscielny J, Ziemer S, Radtke H et al.: A practical concept for preoperative identification of patients with impaired primary hemostasis. Clin Appl Thromb Hemost 2004; 10: 195-204.
6. Lillicrap D, Nair SC, Srivastava A, Rodeghiero F, Pabinger I, Federici AB: Laboratory issues in bleeding disorders. Haemophilia 2006; 12(Suppl 3): 68-75.
7. Peyvandi F, Kaufman RJ, Seligsohn U et al.: Rare bleeding disorders. Haemophilia 2006; 12 (Suppl 3): 137-42.
8. Koscielny J, Radtke H, Ziemer S, Pindur G, Jung F, Kiesewetter H, Wenzel E: Normalisierung der Thrombozytenfunktion durch Desmopressin. Präoperativer Einsatz bei durch Acetylsalicylsäure (ASS) und nichtsteroidale Analgetika induzierter Thrombozytopathie. Anästhesie und Intensivmedizin (A-naesth Intens Care) 1995; 36: 205-10.
9. Jackson CM, White GC: Scientific and standardization committee communication: a reference system approach to future standardization of laboratory tests for hemostasis. Posted on ISTH Website 2001, http://www.med.unc.edu/isth/
10. Fressinaud E, Vayradier A, Truchaud F et al.: Screening for von Willebrand disease with a new analyzer using high shear stress: a study of 60 cases. Blood 1998; 9: 1325-31.
11. Favaloro EJ: The utility of the PFA-100 in the identification of von Willebrand disease: a concise review. Semin Thromb Hemost 2006; 32: 537-45.
12. Mani H, Linnemann B, Luxembourg B, Kirchmayr K, Lindhoff-Last E: Response to aspirin and clopidogrel monitored with different platelet function methods. Platelets 2006;17: 303-10.
13. Reininger AJ: Primary haemostasis and its assessment by laboratory tests. Hämostaseologie 2006; 1: 42-7.
14. Hayward CPM, Harrison P, Cattaneo M, Ortel TL, Rao AK: Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J Thromb Haemost 2006; 4: 312-9.
15. Fattorutto M, Pradier O, Schmartz D, Ickx B, Barvais L: Does the platelet function analyser (PFA-100®) predict blood loss after cardiopulmonary bypass? Br J Anaesth 2003; 90: 692-3.
16. Wahba A, Sander S, Birnbaum DE: Are in-vitro platelet function tests useful in predicting blood loss following open heart surgery? Thorac Cardiovasc Surg 1998; 46: 228-31.
17. Cammerer U, Dietrich W, Rampf T, Braun SL, Richter JA: The predictive value of modified computerized thromboelastography and platelet function analysis for postoperative blood loss in routine cardiac surgery. Anesth Analg 2003; 96: 51-7.
18. Topol EJ, Gum P, Kottke-Marchant K: Determination of the natural history of aspirin resistance among stable patients with cardiovascular disease: Reply. J Am Coll Cardiol 2003; 42: 1336-7.
19. Nordstrom M, Lindblad B, Bergqvist D, Kjellstrom T: A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med 1992; 232: 155-60.
20. Bertina RM, Koeleman BP, Koster T et al.: Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-7.
21. Heeb MJ, Kojima Y, Greengard JS, Griffin JH: Activated protein C resistance: molecular mechanisms based on studies using purified Gln506-factor V. Blood 1995; 85: 3405-11.
22. Aparicio C, Dahlbäck B: Molecular mechanisms of activated protein C resistance. Properties of factor V isolated from an individual with homozygosity for the Arg506 to Gln mutation in the factor V gene. Biochem J 1996; 313: 467-72.
23. Dahlbäck B, Carlsson M, Svensson PJ: Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-8.
24. Schroder W, Koesling M, Wulff K, Wehnert M, Herrmann FH: Large-scale screening for factor V Leiden mutation in a northeastern German population. Haemostasis 1996; 26: 233-6.
25. Griffin JH, Evatt BL, Wideman C, Fernandez JA: Anticoagulant protein C pathway defective in a majority of thrombophilic patients. Blood 1993; 82: 1989-93.